RxDoctor Payments Data

David Hernandez, MD

Urology · Tampa, FLNPI 1063564060

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (40.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Terumo Medical Corporation at 42.4% of the total. Reporting peaked in 2019 at $6,745 and has fallen 64.1% since, to $2,421 in 2025.

$23,324in general payments, 2019–2025

Across 107 payments — averaging $217.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Terumo Medical Corporation$10K
  • Travere Therapeutics, Inc.$6K
  • Boston Scientific$3K
  • Coloplast$1K
  • Procept Biorobotics Corporation$688
  • Calyxo, Inc.$582
  • plus $2K from 14 others
$138,525in research payments, 2019–2025

Across 2 payments — averaging $69,262 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • C. R. Bard, Inc. & Subsidiaries$133K
  • Davol Inc.$5K

What the payments were for

  • Consulting fees$9,35040%
  • Speaking & faculty fees$5,05022%
  • Travel & lodging$1,9688%
  • Food & beverage$6,74429%
  • Education$2121%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,324 in reported general payments places this provider in the 85th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$145,409
Medicare patients
343
Services billed
1,098

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron76$57,556
GemtesaVibegron12$9,968
Tamsulosin Hcl337$5,239
Methenamine Hippurate56$4,345
Finasteride221$3,445
Potassium Citrate ErPotassium Citrate25$2,714
Alfuzosin Hcl ErAlfuzosin Hcl38$1,148
Estradiol19$865
Tadalafil27$854
Testosterone Cypionate25$796
Trospium Chloride15$681
Oxybutynin Chloride26$401
Chlorthalidone18$315
Sildenafil Citrate27$292
Cephalexin19$129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$421$57,55676 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 urology providers in Florida.

Other urology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →